Novo Nordisk closes Dicerna acquisition deal

Novo Nordisk has completed the acquisition of Dicerna Pharmaceuticals, which is the Danish firm's biggest acquisition so far.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Novo Nordisk has closed the acquisition deal of Dicerna Pharmaceuticals, with which the Danish firm has collaborated to develop potential RNA drugs since 2019, Novo Nordisk announces in a press release on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading